Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, Stavudine, HIV Protease Inhibitors, Ritonavir, Lamivudine, Indinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Have a CD4 cell count of 75 cells/mm3 or more and a viral load of 5,000 copies/ml or more. Are age 16 or older (consent of a parent or guardian required if under 18). Agree to practice abstinence or use barrier methods of birth control (such as condoms). Are willing to stop taking all anti-HIV drugs except study drugs. (Patients may be able to continue taking drugs for other infections.) Exclusion Criteria Patients will not be eligible for this study if they: Have cancer, lung disease, severe hepatitis, or active AIDS-related infections. (Certain AIDS-related infections such as Kaposi's sarcoma may be allowed). Have ever taken 3TC, abacavir (ABC), or a protease inhibitor (such as IDV or RTV). Have changed their medications in the last 2 weeks. Are allergic to IDV, RTV, d4T, or 3TC. Have used certain medications (see the technical summary for more detail). Are pregnant or breast-feeding.
Sites / Locations
- Univ of Alabama at Birmingham
- Apogee Med Group
- Univ of California at San Francisco Gen Hosp
- HIV Institute / Davies Med Ctr
- Kaiser Foundation Hospital
- Univ of Miami School of Medicine
- AIDS Research Alliance - Chicago
- Tulane Univ School of Medicine
- CRI New England
- Bronx Lebanon Hosp Ctr
- Montefiore Med Ctr
- SUNY Health Sciences Ctr
- Chelsea Village Med Ctr
- Liberty Med Group
- St Lukes / Roosevelt Hosp / HIV Center
- Mount Sinai Med Ctr
- Mark Watkins
- Univ of Texas / Thomas Street Clinic